Atlantic International (ATLN)
NASDAQ:ATLN
Want to see ATLN full AI Analyst Report?
ATLN Stock Chart & Stats
$4.45
$0.18(3.08%)
At close: 4:00 PM EST
$4.45
$0.18(3.08%)
Day’s Range― - ―
52-Week Range$0.60 - $5.25
Previous Close$6.28
Volume7.10K
Average Volume (3M)364.23K
Market Cap
$55.27M
Enterprise Value$157.32M
Total Cash (Recent Filing)$81.13K
Total Debt (Recent Filing)$38.36M
Price to Earnings (P/E)―
Beta-0.58
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.08
Shares Outstanding79,358,270
10 Day Avg. Volume70,257
30 Day Avg. Volume364,234
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-2.27
Price to Sales (P/S)0.17
P/FCF Ratio-16.34
Enterprise Value/Market Cap2.85
Enterprise Value/Revenue0.36
Enterprise Value/Gross Profit3.42
Enterprise Value/Ebitda-3.60
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.61
Revenue Forecast (FY)$481.08M
Bulls Say, Bears Say
Bulls Say
Institutional Preferred Financing Provides LiquidityThe $5.6M Series B preferred financing delivers immediate working capital and institutional backing, increasing runway for operating needs and strategic options. Structurally, senior preferred capital can stabilize near-term liquidity and enable time to pursue operational improvements or additional financing.
Total Debt Has Declined Versus Prior YearsMaterial reduction in total debt lowers interest and covenant pressure and modestly improves solvency metrics. Over multiple months this deleveraging reduces short-term refinancing risk and supports flexibility for restructuring or targeted investments if the company sustains operational improvements.
Cash Burn Trend Improved In The Most Recent YearA smaller negative operating and free cash flow suggests management has begun to curb cash outflows or improve cash conversion. If sustained, this trend supports a path toward break-even funding needs and reduces reliance on frequent dilutive financings over a 2–6 month horizon.
Bears Say
Persistent Negative Shareholders' EquityNegative equity reflects cumulative losses and materially constrains financial flexibility, making debt metrics unreliable and increasing insolvency risk. Over months this hampers access to traditional credit, forces reliance on subordinated or dilutive capital, and weakens stakeholder confidence.
Consistent Negative Operating And Free Cash FlowOngoing negative operating and free cash flow indicate the core business is not self-funding. Persistent cash burn necessitates repeated external financing, limits reinvestment in growth or R&D, and increases dilution risk and strategic fragility if adverse conditions persist.
Creditor Litigation And Governance RiskActive litigation with a creditor seeking control and the COO's resignation create governance and operational uncertainty. Such disputes can divert management, threaten asset control or restructuring outcomes, and materially disrupt long-term execution and stakeholder relationships.
Atlantic International News
ATLN FAQ
What was Atlantic International’s price range in the past 12 months?
Atlantic International lowest stock price was $0.60 and its highest was $5.25 in the past 12 months.
What is Atlantic International’s market cap?
Atlantic International’s market cap is $55.27M.
When is Atlantic International’s upcoming earnings report date?
Atlantic International’s upcoming earnings report date is Aug 13, 2026 which is in 60 days.
How were Atlantic International’s earnings last quarter?
Currently, no data Available
Is Atlantic International overvalued?
According to Wall Street analysts Atlantic International’s price is currently Overvalued.
Does Atlantic International pay dividends?
Atlantic International does not currently pay dividends.
What is Atlantic International’s EPS estimate?
Atlantic International’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Atlantic International have?
Atlantic International has 79,358,270 shares outstanding.
What happened to Atlantic International’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Atlantic International?
Currently, no hedge funds are holding shares in ATLN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Atlantic International Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.00%
12-Months-Change
Fundamentals
Return on Equity
274.33%
Trailing 12-Months
Asset Growth
-7.88%
Trailing 12-Months
Company Description
Atlantic International
Based in Billerica, Massachusetts, and established in 2013, Atlantic International Corp. (which operated as SeqLL Inc. until its name change in June 2024) underwent a significant corporate change on June 18, 2024, when it was acquired by Lyneer Investments, LLC, via a reverse merger. The company operates within the life sciences sector, providing specialized instrumentation and research services. Its primary focus is on generating innovative scientific assets and proprietary intellectual property across various "omics" disciplines. Central to its offerings is the True Single Molecule Sequencing (tSMS) platform. This advanced technology provides a unique single-molecule approach to DNA and RNA sequencing by directly detecting nucleic acids. It empowers researchers to analyze billions of individual molecules within a single experiment, ensuring the generation of highly accurate and reproducible data. Atlantic International's sophisticated solutions cater to diverse applications, including biomarker discovery and the development of diagnostic assays. Its clientele spans academic institutions (such as universities), governmental research centers, and leading companies in the biotechnology and pharmaceutical industries. The company also fosters key collaborations, including an R&D agreement with the U.S. Department of Justice's Federal Bureau of Investigation to assess the forensic potential of direct RNA sequencing using its tSMS platform, and a partnership with the Weizmann Institute of Science to advance and implement cutting-edge single-molecule technologies.
Technical Analysis
Ownership Overview
24.97% Insiders
1.07% Mutual Funds
0.03% Other Institutional Investors
72.85% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---